No Data
Chengdu Pilot: Announcement on the 2024 Annual Results Report of Chengdu Pilot Pharmaceutical Development Co., Ltd.
Chengdu Pilot Drug Development Co., Ltd. 2024 Annual Performance Report Announcement
Hitgen Inc. (688222.SH): The net income for the year 2024 is 50.9366 million yuan, an increase of 25.09% year-on-year.
On February 27, Gelonghui reported that Hitgen Inc. (688222.SH) disclosed its performance forecast for 2024. During the reporting period, the company achieved revenue of 426.9869 million yuan, a year-on-year increase of 14.99%; net income attributable to the parent company's owners was 50.9366 million yuan, a year-on-year increase of 25.09%; and net income attributable to the parent company's owners after deducting non-recurring gains and losses was 55.3698 million yuan, a year-on-year increase of 1,504.05%. During the reporting period, the commercial projects of the company's various technology platforms steadily advanced, and research projects progressed smoothly, contributing to the growth of main business revenue.
Guosen: Focus on AI + Medical, high-quality innovation, and value symbols with stable performance.
Guosen remains bullish on companies with differentiated innovation capabilities and overseas potential.
China Merchants: The blue ocean of AI in pharmaceuticals, with AI assisting the entire process of new drug development.
Previously, the application of AI technology in the drug development process mainly focused on the drug discovery stage. With the application of large model technologies like Deepseek, the value of AI in the clinical stage will gradually become evident.
Hitgen Inc. (688222.SH): Boyi Xintian has cumulatively reduced its shareholding by 1.55%.
On February 14, GeLong Hui reported that Hitgen Inc. (688222.SH) announced it received a notice from shareholder Bo Yi Xin Tian on February 14, 2025. During this shareholding plan period, Bo Yi Xin Tian cumulatively reduced its holdings in the company by 6,217,637 shares through centralized bidding and block trading, accounting for 1.55% of the company's total share capital. After this shareholding reduction is completed, Bo Yi Xin Tian will no longer hold any shares in the company, and the shareholding plan has been implemented.
Time To Worry? Analysts Are Downgrading Their HitGen Inc. (SHSE:688222) Outlook
